학술논문

Ramucirumab (RAM) as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP): An analysis of AFP kinetics in the phase III REACH-2 study.
Document Type
Journal
Source
JOURNAL OF CLINICAL ONCOLOGY; FEB 1 2019, 37 4, 2p. Supplement: S
Subject
Language
English
ISSN
15277755